Safety and Effectiveness of COVID-19 Vaccines During Pregnancy: A Living Systematic Review and Meta-analysis.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
15 Jul 2024
15 Jul 2024
Historique:
accepted:
04
06
2024
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
15
7
2024
Statut:
aheadofprint
Résumé
Pregnant persons are susceptible to significant complications following COVID-19, even death. However, worldwide COVID-19 vaccination coverage during pregnancy remains suboptimal. This study assessed the safety and effectiveness of COVID-19 vaccines administered to pregnant persons and shared this evidence via an interactive online website. We followed Cochrane methods to conduct this living systematic review. We included studies assessing the effects of COVID-19 vaccines in pregnant persons. We conducted searches every other week for studies until October 2023, without restrictions on language or publication status, in ten databases, guidelines, preprint servers, and COVID-19 websites. The reference lists of eligible studies were hand searched to identify additional relevant studies. Pairs of review authors independently selected eligible studies using the web-based software COVIDENCE. Data extraction and risk of bias assessment were performed independently by pairs of authors. Disagreements were resolved by consensus. We performed random-effects meta-analyses of adjusted relative effects for relevant confounders of comparative studies and proportional meta-analyses to summarize frequencies from one-sample studies using R statistical software. We present the GRADE certainty of evidence from comparative studies. Findings are available on an interactive living systematic review webpage, including an updated evidence map and real-time meta-analyses customizable by subgroups and filters. We included 177 studies involving 638,791 participants from 41 countries. Among the 11 types of COVID-19 vaccines identified, the most frequently used platforms were mRNA (154 studies), viral vector (51), and inactivated virus vaccines (17). Low to very low-certainty evidence suggests that vaccination may result in minimal to no important differences compared to no vaccination in all assessed maternal and infant safety outcomes from 26 fewer to 17 more events per 1000 pregnant persons, and 13 fewer to 9 more events per 1000 neonates, respectively. We found statistically significant reductions in emergency cesarean deliveries (9%) with mRNA vaccines, and in stillbirth (75-83%) with mRNA/viral vector vaccines. Low to very low-certainty evidence suggests that vaccination during pregnancy with mRNA vaccines may reduce severe cases or hospitalizations in pregnant persons with COVID-19 (72%; 95% confidence interval [CI] 42-86), symptomatic COVID-19 (78%; 95% CI 21-94), and virologically confirmed SARS-CoV-2 infection (82%; 95% CI 39-95). Reductions were lower with other vaccine types and during Omicron variant dominance than Alpha and Delta dominance. Infants also presented with fewer severe cases or hospitalizations due to COVID-19 and laboratory-confirmed SARS-CoV-2 infection (64%; 95% CI 37-80 and 66%; 95% CI 37-81, respectively). We found a large body of evidence supporting the safety and effectiveness of COVID-19 vaccines during pregnancy. While the certainty of evidence is not high, it stands as the most reliable option available, given the current absence of pregnant individuals in clinical trials. Results are shared in near real time in an accessible and interactive format for scientists, decision makers, clinicians, and the general public. This living systematic review highlights the relevance of continuous vaccine safety and effectiveness monitoring, particularly in at-risk populations for COVID-19 impact such as pregnant persons, during the introduction of new vaccines. PROSPERO: CRD42021281290.
Sections du résumé
BACKGROUND
BACKGROUND
Pregnant persons are susceptible to significant complications following COVID-19, even death. However, worldwide COVID-19 vaccination coverage during pregnancy remains suboptimal.
OBJECTIVE
OBJECTIVE
This study assessed the safety and effectiveness of COVID-19 vaccines administered to pregnant persons and shared this evidence via an interactive online website.
METHODS
METHODS
We followed Cochrane methods to conduct this living systematic review. We included studies assessing the effects of COVID-19 vaccines in pregnant persons. We conducted searches every other week for studies until October 2023, without restrictions on language or publication status, in ten databases, guidelines, preprint servers, and COVID-19 websites. The reference lists of eligible studies were hand searched to identify additional relevant studies. Pairs of review authors independently selected eligible studies using the web-based software COVIDENCE. Data extraction and risk of bias assessment were performed independently by pairs of authors. Disagreements were resolved by consensus. We performed random-effects meta-analyses of adjusted relative effects for relevant confounders of comparative studies and proportional meta-analyses to summarize frequencies from one-sample studies using R statistical software. We present the GRADE certainty of evidence from comparative studies. Findings are available on an interactive living systematic review webpage, including an updated evidence map and real-time meta-analyses customizable by subgroups and filters.
RESULTS
RESULTS
We included 177 studies involving 638,791 participants from 41 countries. Among the 11 types of COVID-19 vaccines identified, the most frequently used platforms were mRNA (154 studies), viral vector (51), and inactivated virus vaccines (17). Low to very low-certainty evidence suggests that vaccination may result in minimal to no important differences compared to no vaccination in all assessed maternal and infant safety outcomes from 26 fewer to 17 more events per 1000 pregnant persons, and 13 fewer to 9 more events per 1000 neonates, respectively. We found statistically significant reductions in emergency cesarean deliveries (9%) with mRNA vaccines, and in stillbirth (75-83%) with mRNA/viral vector vaccines. Low to very low-certainty evidence suggests that vaccination during pregnancy with mRNA vaccines may reduce severe cases or hospitalizations in pregnant persons with COVID-19 (72%; 95% confidence interval [CI] 42-86), symptomatic COVID-19 (78%; 95% CI 21-94), and virologically confirmed SARS-CoV-2 infection (82%; 95% CI 39-95). Reductions were lower with other vaccine types and during Omicron variant dominance than Alpha and Delta dominance. Infants also presented with fewer severe cases or hospitalizations due to COVID-19 and laboratory-confirmed SARS-CoV-2 infection (64%; 95% CI 37-80 and 66%; 95% CI 37-81, respectively).
CONCLUSIONS
CONCLUSIONS
We found a large body of evidence supporting the safety and effectiveness of COVID-19 vaccines during pregnancy. While the certainty of evidence is not high, it stands as the most reliable option available, given the current absence of pregnant individuals in clinical trials. Results are shared in near real time in an accessible and interactive format for scientists, decision makers, clinicians, and the general public. This living systematic review highlights the relevance of continuous vaccine safety and effectiveness monitoring, particularly in at-risk populations for COVID-19 impact such as pregnant persons, during the introduction of new vaccines.
CLINICAL TRIAL REGISTRATION
BACKGROUND
PROSPERO: CRD42021281290.
Identifiants
pubmed: 39009928
doi: 10.1007/s40264-024-01458-w
pii: 10.1007/s40264-024-01458-w
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bill and Melinda Gates Foundation
ID : INV008443
Informations de copyright
© 2024. The Author(s).
Références
WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/ . Accessed 20 Apr 2024.
World Health Organization, Others. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply: an approach to inform planning and subsequent recommendations based on epidemiological setting and vaccine supply scenarios, first issued 20 October 2020, latest update 16 July 2021. World Health Organization; 2021. Available from: https://apps.who.int/iris/handle/10665/342917 . Accessed 20 Apr 2024.
COVID-19 vaccines. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines . Accessed 20 Apr 2024.
World Health Organization. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines: an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios. Updated 10 November 2023. World Health Organization; 2023. Report No.: WHO/2019-nCoV/Vaccines/SAGE/Prioritization/2022.1. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1 . Accessed 20 Apr 2024.
WHO. COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines . Accessed 20 Apr 2024.
Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F, et al. Vaccines to prevent COVID-19: a living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. PLoS ONE. 2022;17: e0260733. https://doi.org/10.1371/journal.pone.0260733 .
doi: 10.1371/journal.pone.0260733
pubmed: 35061702
pmcid: 8782520
Ciapponi A, Bardach A, Mazzoni A, Alconada T, Anderson SA, Argento FJ, et al. Safety of components and platforms of COVID-19 vaccines considered for use in pregnancy: a rapid review. Vaccine. 2021;39:5891–908. https://doi.org/10.1016/j.vaccine.2021.08.034 .
doi: 10.1016/j.vaccine.2021.08.034
pubmed: 34489131
pmcid: 8360993
Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status: United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1641–7. https://doi.org/10.15585/mmwr.mm6944e3 .
doi: 10.15585/mmwr.mm6944e3
pubmed: 33151921
pmcid: 7643892
Ciapponi A, Bardach A, Comandé D, Berrueta M, Argento FJ, Rodriguez Cairoli F, et al. COVID-19 and pregnancy: an umbrella review of clinical presentation, vertical transmission, and maternal and perinatal outcomes. PLoS ONE. 2021;16: e0253974. https://doi.org/10.1371/journal.pone.0253974 .
doi: 10.1371/journal.pone.0253974
pubmed: 34185807
pmcid: 8241118
Vouga M, Favre G, Martinez-Perez O, Pomar L, Acebal LF, Abascal-Saiz A, et al. Maternal outcomes and risk factors for COVID-19 severity among pregnant women. Sci Rep. 2021;11:13898. https://doi.org/10.1038/s41598-021-92357-y .
doi: 10.1038/s41598-021-92357-y
pubmed: 34230507
pmcid: 8260739
Allotey J, Fernandez S, Bonet M, Stallings E, Yap M, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ. 2019. https://doi.org/10.1136/bmj.m3320 .
doi: 10.1136/bmj.m3320
pubmed: 30936210
pmcid: 6441866
Smith ER, Oakley E, Grandner GW, Ferguson K, Farooq F, Afshar Y, et al. Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection: an individual participant data meta-analysis. BMJ Glob Health. 2023;8: e009495. https://doi.org/10.1136/bmjgh-2022-009495 .
doi: 10.1136/bmjgh-2022-009495
pubmed: 36646475
Sheikh J, Lawson H, Allotey J, Yap M, Balaji R, Kew T, et al. Global variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant women by geographical region and country’s income status: a meta-analysis. BMJ Glob Health. 2022;7: e010060. https://doi.org/10.1136/bmjgh-2022-010060 .
doi: 10.1136/bmjgh-2022-010060
pubmed: 36368768
Jorgensen SCJ, Hernandez A, Fell DB, Austin PC, D’Souza R, Guttmann A, et al. Maternal mRNA COVID-19 vaccination during pregnancy and delta or omicron infection or hospital admission in infants: test negative design study. BMJ. 2023;380: e074035. https://doi.org/10.1136/bmj-2022-074035 .
doi: 10.1136/bmj-2022-074035
pubmed: 36754426
Badell ML, Dude CM, Rasmussen SA, Jamieson DJ. Covid-19 vaccination in pregnancy. BMJ. 2022;378: e069741. https://doi.org/10.1136/bmj-2021-069741 .
doi: 10.1136/bmj-2021-069741
pubmed: 35948352
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019. Available from: https://play.google.com/store/books/details?id=cTqyDwAAQBAJ . Accessed 20 Apr 2024.
Elliott JH, Synnot A, Turner T, Simmonds M, Akl EA, McDonald S, et al. Living systematic review: 1 Introduction: the why, what, when, and how. J Clin Epidemiol. 2017;91:23–30.
doi: 10.1016/j.jclinepi.2017.08.010
pubmed: 28912002
World Health Organization. Regional Office for Europe. Guidance on an adapted evidence to recommendation process for National Immunization Technical Advisory Groups. World Health Organization. Regional Office for Europe; 2022. Report No.: WHO/EURO:2022-5497-45262-64756. Available from: https://apps.who.int/iris/handle/10665/356896 . Accessed 20 Apr 2024.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18: e1003583. https://doi.org/10.1371/journal.pmed.1003583 .
doi: 10.1371/journal.pmed.1003583
pubmed: 33780438
pmcid: 8007028
Kahale LA, Elkhoury R, El Mikati I, Pardo-Hernandez H, Khamis AM, Schünemann HJ, et al. Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal. F1000Res. 2021;10:192.
doi: 10.12688/f1000research.51723.3
pubmed: 35136567
Ciapponi A, Berrueta M, Ballivian J, Bardach A, Mazzoni A, Anderson S, et al. Safety, immunogenicity, and effectiveness of COVID-19 vaccines for pregnant persons: a protocol for systematic review and meta analysis. Medicine. 2023;102: e32954. https://doi.org/10.1097/MD.0000000000032954 .
doi: 10.1097/MD.0000000000032954
pubmed: 36862871
pmcid: 9981247
Covidence. Covidence systematic review software, veritas health innovation. Melbourne (VIC); 2021.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81. https://doi.org/10.1016/j.jbi.2008.08.010 .
doi: 10.1016/j.jbi.2008.08.010
pubmed: 18929686
NIH. Study quality assessment tools. 2020. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools . Accessed 20 Apr 2024.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88. https://doi.org/10.1016/0197-2456(86)90046-2 .
doi: 10.1016/0197-2456(86)90046-2
pubmed: 3802833
The R project for statistical computing. Available from: https://www.R-project.org/ . Accessed 17 Jun 2024.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60. https://doi.org/10.1136/ebmental-2019-300117 .
doi: 10.1136/ebmental-2019-300117
pubmed: 31563865
pmcid: 10231495
Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1–48. Available from: https://www.jstatsoft.org/article/view/v036i03 . Accessed 20 Apr 2024.
Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4:1686.
doi: 10.21105/joss.01686
Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607–11.
doi: 10.1214/aoms/1177729756
Taylor I, Knowelden J. Principles of epidemiology. Little, Brown; 1964. Available from: https://play.google.com/store/books/details?id=STRrAAAAMAAJ . Accessed 20 Apr 2024.
Bonhoeffer J, Kochhar S, Hirschfeld S, Heath PT, Jones CE, Bauwens J, et al. Global alignment of immunization safety assessment in pregnancy: the GAIA project. Vaccine. 2016;34:5993–7. https://doi.org/10.1016/j.vaccine.2016.07.006 .
doi: 10.1016/j.vaccine.2016.07.006
pubmed: 27751641
Schünemann G, Vist J, Higgins N, Santesso J, Deeks P. Chapter 14: completing ‘summary of findings’ tables and grading the certainty of the evidence. In: Higgins J, Thomas J, editors. Cochrane handbook for systematic reviews of interventions version. London: Cochrane; 2019. p. 6.
Safe in pregnancy: living systematic review. Available from: https://safeinpregnancy.org/lsr/ . [Accessed 20 Apr 2024.]
Chang W, Cheng J, Allaire J, Xie Y, McPherson J. Shiny: web application framework for R. R package version.
Hui L, Marzan MB, Rolnik DL, Potenza S, Pritchard N, Said JM, et al. Reductions in stillbirths and preterm birth in COVID-19-vaccinated women: a multicenter cohort study of vaccination uptake and perinatal outcomes. Am J Obstet Gynecol. 2023;228:585.e1-585.e16. https://doi.org/10.1016/j.ajog.2022.10.040 .
doi: 10.1016/j.ajog.2022.10.040
pubmed: 36336084
Fell DB, Dimanlig-Cruz S, Regan AK, Håberg SE, Gravel CA, Oakley L, et al. Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study. BMJ. 2022;378: e071416. https://doi.org/10.1136/bmj-2022-071416 .
doi: 10.1136/bmj-2022-071416
pubmed: 35977737
Magnus MC, Örtqvist AK, Dahlqwist E, Ljung R, Skår F, Oakley L, et al. Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes. JAMA. 2022;327:1469–77. https://doi.org/10.1001/jama.2022.3271 .
doi: 10.1001/jama.2022.3271
pubmed: 35323851
pmcid: 8949721
Kharbanda EO, Haapala J, DeSilva M, Vazquez-Benitez G, Vesco KK, Naleway AL, et al. Spontaneous abortion following COVID-19 vaccination during pregnancy. JAMA. 2021;326:1629–31. https://doi.org/10.1001/jama.2021.15494 .
doi: 10.1001/jama.2021.15494
pubmed: 34495304
pmcid: 8427483
Magnus MC, Gjessing HK, Eide HN, Wilcox AJ, Fell DB, Håberg SE. COVID-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med. 2021;385:2008–10. https://doi.org/10.1056/NEJMc2114466 .
doi: 10.1056/NEJMc2114466
pubmed: 34670062
Citu IM, Citu C, Gorun F, Sas I, Bratosin F, Motoc A, et al. The risk of spontaneous abortion does not increase following first trimester mRNA COVID-19 vaccination. J Clin Med Res. 2022. https://doi.org/10.3390/jcm11061698 .
doi: 10.3390/jcm11061698
Dick A, Rosenbloom JI, Gutman-Ido E, Lessans N, Cahen-Peretz A, Chill HH. Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study. BMC Pregnancy Childbirth. 2022;22:166. https://doi.org/10.1186/s12884-022-04505-5 .
doi: 10.1186/s12884-022-04505-5
pubmed: 35227233
pmcid: 8884102
Wainstock T, Yoles I, Sergienko R, Sheiner E. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. Vaccine. 2021;39:6037–40. https://doi.org/10.1016/j.vaccine.2021.09.012 .
doi: 10.1016/j.vaccine.2021.09.012
pubmed: 34531079
pmcid: 8421099
Peretz-Machluf R, Hirsh-Yechezkel G, Zaslavsky-Paltiel I, Farhi A, Avisar N, Lerner-Geva L, et al. Obstetric and neonatal outcomes following COVID-19 vaccination in pregnancy. J Clin Med Res. 2022. https://doi.org/10.3390/jcm11092540 .
doi: 10.3390/jcm11092540
Blakeway H, Prasad S, Kalafat E, Heath PT, Ladhani SN, Le Doare K, et al. COVID-19 vaccination during pregnancy: coverage and safety. Am J Obstet Gynecol. 2022;226(236):e1-14. https://doi.org/10.1016/j.ajog.2021.08.007 .
doi: 10.1016/j.ajog.2021.08.007
Dick A, Rosenbloom JI, Karavani G, Gutman-Ido E, Lessans N, Chill HH. Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy. Am J Obstet Gynecol MFM. 2022;4: 100637. https://doi.org/10.1016/j.ajogmf.2022.100637 .
doi: 10.1016/j.ajogmf.2022.100637
pubmed: 35398583
pmcid: 8988438
Fell DB, Dhinsa T, Alton GD, Török E, Dimanlig-Cruz S, Regan AK, et al. Association of COVID-19 vaccination in pregnancy with adverse peripartum outcomes. JAMA. 2022;327:1478–87. https://doi.org/10.1001/jama.2022.4255 .
doi: 10.1001/jama.2022.4255
pubmed: 35323842
pmcid: 8949767
Brinkley E, Mack CD, Albert L, Knuth K, Reynolds MW, Toovey S, et al. COVID-19 vaccinations in pregnancy: comparative evaluation of acute side effects and self-reported impact on quality of life between pregnant and nonpregnant women in the United States. Am J Perinatol. 2022;39:1750–3. https://doi.org/10.1055/s-0042-1748158 .
doi: 10.1055/s-0042-1748158
pubmed: 35523212
Kachikis A, Englund JA, Covelli I, Frank Y, Haghighi C, Singleton M, et al. Analysis of vaccine reactions after COVID-19 vaccine booster doses among pregnant and lactating individuals. JAMA Netw Open. 2022;5: e2230495. https://doi.org/10.1001/jamanetworkopen.2022.30495 .
doi: 10.1001/jamanetworkopen.2022.30495
pubmed: 36074467
pmcid: 9459662
Shapiro Ben David S, Baruch Gez S, Rahamim-Cohen D, Shamir-Stein N, Lerner U, Ekka Zohar A. Immediate side effects of Comirnaty COVID-19 vaccine: a nationwide survey of vaccinated people in Israel, December 2020 to March 2021. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.13.2100540 .
doi: 10.2807/1560-7917.ES.2022.27.13.2100540
pubmed: 35362408
pmcid: 8973016
Goldshtein I, Steinberg DM, Kuint J, Chodick G, Segal Y, Shapiro ben David S, et al. Association of BNT162b2 COVID-19 vaccination during pregnancy with neonatal and early infant outcomes. JAMA Pediatr. 2022;176:470–7. https://doi.org/10.1001/jamapediatrics.2022.0001 .
doi: 10.1001/jamapediatrics.2022.0001
pubmed: 35142809
pmcid: 8832306
Lipkind HS, Vazquez-Benitez G, DeSilva M, Vesco KK, Ackerman-Banks C, Zhu J, et al. Receipt of COVID-19 vaccine during pregnancy and preterm or small-for-gestational-age at birth: eight integrated health care organizations, United States, December 15, 2020-July 22, 2021. MMWR Morb Mortal Wkly Rep. 2022;71:26–30. https://doi.org/10.15585/mmwr.mm7101e1 .
doi: 10.15585/mmwr.mm7101e1
pubmed: 34990445
pmcid: 8735559
Paixao ES, Wong KLM, Alves FJO, de Araújo OV, Cerqueira-Silva T, Júnior JB, et al. CoronaVac vaccine is effective in preventing symptomatic and severe COVID-19 in pregnant women in Brazil: a test-negative case-control study. BMC Med. 2022;20:146. https://doi.org/10.1186/s12916-022-02353-w .
doi: 10.1186/s12916-022-02353-w
pubmed: 35379250
pmcid: 8979723
Dagan N, Barda N, Biron-Shental T, Makov-Assif M, Key C, Kohane IS, et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat Med. 2021;27:1693–5. https://doi.org/10.1038/s41591-021-01490-8 .
doi: 10.1038/s41591-021-01490-8
pubmed: 34493859
Florentino PTV, Alves FJO, Cerqueira-Silva T, de Araújo OV, Júnior JBS, Penna GO, et al. Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil. Lancet Infect Dis. 2022;22:1669–70. https://doi.org/10.1016/S1473-3099(22)00728-9 .
doi: 10.1016/S1473-3099(22)00728-9
pubmed: 36356609
pmcid: 9640198
Morgan JA, Biggio JR Jr, Martin JK, Mussarat N, Chawla HK, Puri P, et al. Maternal outcomes after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vaccinated compared with unvaccinated pregnant patients. Obstet Gynecol. 2022;139:107–9. https://doi.org/10.1097/AOG.0000000000004621 .
doi: 10.1097/AOG.0000000000004621
pubmed: 34644272
Villar J, Soto Conti CP, Gunier RB, Ariff S, Craik R, Cavoretto PI, et al. Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. Lancet. 2023;401:447–57. https://doi.org/10.1016/S0140-6736(22)02467-9 .
doi: 10.1016/S0140-6736(22)02467-9
pubmed: 36669520
pmcid: 9910845
Bosworth ML, Schofield R, Ayoubkhani D, Charlton L, Nafilyan V, Khunti K, et al. Vaccine effectiveness for prevention of covid-19 related hospital admission during pregnancy in England during the alpha and delta variant dominant periods of the SARS-CoV-2 pandemic: population based cohort study. BMJ Med. 2023;2: e000403. https://doi.org/10.1136/bmjmed-2022-000403 .
doi: 10.1136/bmjmed-2022-000403
pubmed: 37564827
pmcid: 10410807
Schrag SJ, Verani JR, Dixon BE, Page JM, Butterfield KA, Gaglani M, et al. Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of delta and omicron variant predominance in the United States. JAMA Netw Open. 2022;5: e2233273. https://doi.org/10.1001/jamanetworkopen.2022.33273 .
doi: 10.1001/jamanetworkopen.2022.33273
pubmed: 36156146
pmcid: 9513651
Danino D, Ashkenazi-Hoffnung L, Diaz A, Erps AD, Eliakim-Raz N, Avni YS, et al. Effectiveness of BNT162b2 vaccination during pregnancy in preventing hospitalization for severe acute respiratory syndrome coronavirus 2 in infants. J Pediatr. 2023;254:48-53.e1. https://doi.org/10.1016/j.jpeds.2022.09.059 .
doi: 10.1016/j.jpeds.2022.09.059
pubmed: 36252864
Halasa NB, Olson SM, Staat MA, Newhams MM, Price AM, Pannaraj PS, et al. Maternal vaccination and risk of hospitalization for covid-19 among infants. N Engl J Med. 2022;387:109–19. https://doi.org/10.1056/nejmoa2204399 .
doi: 10.1056/nejmoa2204399
pubmed: 35731908
Ciapponi A, Berrueta M, Bardach A, Mazzoni A, Anderson SA, Argento FJ, et al. Safety of COVID-19 vaccines during pregnancy: a systematic review and meta-analysis. 2022. Available from: https://papers.ssrn.com/abstract=4072487 . Accessed 25 May 2022.
Rahmati M, Yon DK, Lee SW, Butler L, Koyanagi A, Jacob L, et al. Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: a systematic review and meta-analysis. Rev Med Virol. 2023;33: e2434. https://doi.org/10.1002/rmv.2434 .
doi: 10.1002/rmv.2434
pubmed: 36896895
Rimmer MP, Teh JJ, Mackenzie SC, Al Wattar BH. The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis. Hum Reprod. 2023;38:840–52. https://doi.org/10.1093/humrep/dead036 .
doi: 10.1093/humrep/dead036
pubmed: 36794918
pmcid: 10152171
Ding C, Liu Y, Pang W, Zhang D, Wang K, Chen Y. Associations of COVID-19 vaccination during pregnancy with adverse neonatal and maternal outcomes: a systematic review and meta-analysis. Front Public Health. 2023;11:1044031. https://doi.org/10.3389/fpubh.2023.1044031 .
doi: 10.3389/fpubh.2023.1044031
pubmed: 36794075
pmcid: 9922836
Shafiee A, Kohandel Gargari O, Teymouri Athar MM, Fathi H, Ghaemi M, Mozhgani S-H. COVID-19 vaccination during pregnancy: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23:45. https://doi.org/10.1186/s12884-023-05374-2 .
doi: 10.1186/s12884-023-05374-2
pubmed: 36670389
pmcid: 9853484
Zhang D, Huang T, Chen Z, Zhang L, Gao Q, Liu G, et al. Systematic review and meta-analysis of neonatal outcomes of COVID-19 vaccination in pregnancy. Pediatr Res. 2023;94:34–42. https://doi.org/10.1038/s41390-022-02421-0 .
doi: 10.1038/s41390-022-02421-0
pubmed: 36596943
pmcid: 9808682
Tormen M, Taliento C, Salvioli S, Piccolotti I, Scutiero G, Cappadona R, et al. Effectiveness and safety of COVID-19 vaccine in pregnant women: a systematic review with meta-analysis. BJOG. 2023;130:348–57. https://doi.org/10.1111/1471-0528.17354 .
doi: 10.1111/1471-0528.17354
pubmed: 36444098
Hameed I, Khan MO, Nusrat K, Mahmood S, Nashit M, Malik S, et al. Is it safe and effective to administer COVID-19 vaccines during pregnancy? A systematic review and meta-analysis. Am J Infect Control. 2023;51:582–93. https://doi.org/10.1016/j.ajic.2022.08.014 .
doi: 10.1016/j.ajic.2022.08.014
pubmed: 36007670
Hagrass AI, Almadhoon HW, Al-Kafarna M, Almaghary BK, Nourelden AZ, Fathallah AH, et al. Maternal and neonatal safety outcomes after SAR-CoV-2 vaccination during pregnancy: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2022;22:581. https://doi.org/10.1186/s12884-022-04884-9 .
doi: 10.1186/s12884-022-04884-9
pubmed: 35864455
pmcid: 9302221
Carbone L, Trinchillo MG, Di Girolamo R, Raffone A, Saccone G, Iorio GG, et al. COVID-19 vaccine and pregnancy outcomes: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2022;159:651–61. https://doi.org/10.1002/ijgo.14336 .
doi: 10.1002/ijgo.14336
pubmed: 35810414
Prasad S, Kalafat E, Blakeway H, Townsend R, O’Brien P, Morris E, et al. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. Nat Commun. 2022;13:2414. https://doi.org/10.1038/s41467-022-30052-w .
doi: 10.1038/s41467-022-30052-w
pubmed: 35538060
pmcid: 9090726
Wu S, Wang L, Dong J, Bao Y, Liu X, Li Y, et al. The dose- and time-dependent effectiveness and safety associated with COVID-19 vaccination during pregnancy: a systematic review and meta-analysis. Int J Infect Dis. 2023;128:335–46. https://doi.org/10.1016/j.ijid.2023.01.018 .
doi: 10.1016/j.ijid.2023.01.018
pubmed: 36707044
pmcid: 9873368
Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021;193:E540–8. https://doi.org/10.1503/cmaj.202604 .
doi: 10.1503/cmaj.202604
pubmed: 33741725
pmcid: 8084555
Katoto PDMC, Brand AS, Byamungu LN, Tamuzi JL, Mahwire TC, Kitenge MK, et al. Safety of COVID-19 Pfizer-BioNtech (BNT162b2) mRNA vaccination in adolescents aged 12–17 years: a systematic review and meta-analysis. Hum Vaccin Immunother. 2022;18:2144039. https://doi.org/10.1080/21645515.2022.2144039 .
doi: 10.1080/21645515.2022.2144039
pubmed: 36367429
pmcid: 9746476
Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, et al. Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials. Infect Dis Poverty. 2021;10:94. https://doi.org/10.1186/s40249-021-00878-5 .
doi: 10.1186/s40249-021-00878-5
pubmed: 34225791
pmcid: 8256217
Zerbo O, Ray GT, Fireman B, Layefsky E, Goddard K, Lewis E, et al. Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first 6 months of life. Res Sq. 2022. https://doi.org/10.21203/rs.3.rs-2143552/v1 .
doi: 10.21203/rs.3.rs-2143552/v1
pubmed: 36299419
pmcid: 9603829
Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, et al. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. Vaccine. 2023;41:5296–303. https://doi.org/10.1016/j.vaccine.2023.06.032 .
doi: 10.1016/j.vaccine.2023.06.032
pubmed: 37451878
DeSilva M, Munoz FM, Mcmillan M, Kawai AT, Marshall H, Macartney KK, et al. Congenital anomalies: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2016;34:6015–26. https://doi.org/10.1016/j.vaccine.2016.03.047 .
doi: 10.1016/j.vaccine.2016.03.047
pubmed: 27435386
pmcid: 5139892